Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Explore this paper's citation graph
Summary
INCB018424 was associated with marked and durable clinical benefits in patients with myelofibrosis for whom no approved therapies existed and was associated with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myelofibrosis.
- Type
- article
- Published
- 2010-09-15
- Cited by
- 1,150
- References
- 30
- Access
- Open access
- OpenAlex
- https://openalex.org/W2123633897
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:19369678
Keywords
Myelofibrosis, Ruxolitinib, Medicine, Janus kinase 2, Myeloproliferative neoplasm
References
- A gain-of-function mutation of JAK2 in myeloproliferative disorders.
- Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.
- Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.
- Gastrosplenic fistula from Hodgkin's lymphoma.
- Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.
- Serum interleukin (IL)‐1, IL‐2, sIL‐2Ra, IL‐6 and thrombopoietin levels in patients with chronic myeloproliferative diseases
- Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
- The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
- The role of cytokines in cancer-related fatigue
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
- New insights into the pathogenesis and drug treatment of myelofibrosis
- The Myelofibrosis Symptom Assessment Form (MFSAF): An Evidence-based Brief Inventory to Measure Quality of Life and Symptomatic Response to Treatment in Myelofibrosis
- The role of cytokines in cancer.
- International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
- E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
- Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders
- Therapeutic potential of JAK2 inhibitors
- Crossroads of cytokine signaling--the chase to stop muscle cachexia.
Cited by
- JAK inhibition in myelofibrosis.
- Janus-Kinase-Hemmer
- Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms.
- Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.
- Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura
- Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.
- Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
- Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes
- Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.
- Ruxolitinib for symptom control in patients with Chronic Lymphocytic leukemia: A Phase II Trial
- “Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
- A Critical Review of the Role and Limitations of JAK Inhibitors in Myelofibrosis Therapy
- Review of Treatment Options for Myelofibrosis: Focus on Ruxolitinib
- Recurring mutations in myeloproliferative neoplasms alter epigenetic regulation of gene expression.
- Computational and mathematical models of the JAK-STAT signal transduction pathway
- BCR-ABL-negative myeloproliferative Neoplasien
- Predictive genomic biomarkers.
- Rational therapeutic options for patients with myeloproliferative neoplasms.
- 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors.
- Macrophage-Related Interaction Pathways in Tumor Stroma
Related papers
- Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study
- Pierwotna mielofibroza – przegląd metod leczniczych
- Sustained Response to Ruxolitinib of Eosinophilia-Associated Myeloproliferative Neoplasm with Translocation t(8;9)(p21;p24)
- Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
- Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm.
- Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms
- Chronic lymphocytic leukemia developing in a patient with Janus kinase 2 V617F mutation positive myeloproliferative neoplasm
- Massive hepatomegaly and involvement by Janus kinase 2–positive myeloproliferative neoplasm
- The promise of Janus kinase inhibitors in the treatment of hematological malignancies
- TYROSINE PHOSPHORYLATED SOCS3 IS UNABLE TO REGULATE THE MYELOPROLIFERATIVE NEOPLASM ASSOCIATED-JAK2 V617F KINASE